Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), unveiled significant findings from its facial injectables portfolio during the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France. The event, running from January 29 to 31, showcased both on-market products and innovations under regulatory review, reaffirming the company’s leadership in aesthetic medicine.

A Focus on Innovation and Personalized Outcomes

"Allergan Aesthetics is driving the future of aesthetic medicine through a focus on scientifically driven innovation", said John Maltman, vice president of global aesthetics medical affairs at Allergan Aesthetics. He emphasized the company’s commitment to addressing patient concerns and enhancing clinical insights for healthcare providers. The data presented at IMCAS 2026 reinforced the company’s dedication to delivering natural, personalized treatment outcomes through its proprietary AA Signature™ approach.

Key Findings Across Facial Injectables

The centerpiece of Allergan Aesthetics’ presentations was nine e-posters highlighting the efficacy, safety, and patient satisfaction associated with its facial injectables portfolio. Among the key products highlighted were:

  • TrenibotulinumtoxinE: A first-in-class botulinum neurotoxin serotype E currently under regulatory review. Data from Phase 3 trials demonstrated its ability to deliver rapid results with a short-duration effect for glabellar lines.
  • BOTOX® Cosmetic (onabotulinumtoxinA): Findings from Phase 4 studies underlined patient satisfaction and the benefits of long-term use for upper facial lines, with a focus on achieving natural outcomes.
  • Hyaluronic Acid-Based Fillers and Biostimulatory Injectables: Results showcased their potential in skin rejuvenation and multimodal treatment approaches.

The posters provided detailed analyses, including subgroup findings by age, sex, and prior neurotoxin usage.

Highlights from Poster Presentations

Key presentations included:

  1. Age-Related Efficacy Outcomes of TrenibotulinumtoxinE: This pooled Phase 3 analysis explored treatment efficacy for glabellar lines across age categories.
  2. Efficacy in Male Participants: A Phase 3 subgroup analysis reviewed outcomes specific to male patients undergoing TrenibotulinumtoxinE treatment.
  3. Patient-Reported Satisfaction: A Phase 3 randomized trial revealed high patient satisfaction, natural-looking results, and psychological benefits associated with TrenibotulinumtoxinE.
  4. Long-Term OnabotulinumtoxinA Use: A global retrospective study highlighted motivating factors for patients seeking repeated treatments for upper facial lines.

Educational Symposia and Live Demonstrations

Beyond the presentation of data, Allergan Aesthetics hosted two educational symposia featuring global experts, interactive panel discussions, and live injection sessions. These sessions explored advancements in botulinum toxin research and the application of the AA Signature™ multimodal treatment strategy.

  • The Global Medical Affairs Symposium, titled The Heritage and Future of Botulinum Toxin: Next Generation Toxin and Expanding Horizons, featured discussions on emerging trends in the field and long-term patient journeys.
  • The Allergan Medical Institute (AMI) Symposium, AA Signature™: When Patients’ Aspirations Meet Clinical Reality, focused on real-world applications of Allergan Aesthetics’ portfolio to achieve transformative results.

Interactive Experiences at IMCAS

IMCAS

Attendees of IMCAS 2026 were encouraged to visit the Allergan Aesthetics booth (E130) to engage with the company’s interactive presentations, including live demonstrations of the AA Signature™ approach to treatment. Delegates also had the opportunity to connect directly with experts and learn more about the science and innovation behind Allergan Aesthetics’ expanding portfolio.

Conclusion

With the unveiling of its latest data at IMCAS 2026, Allergan Aesthetics reinforced its commitment to advancing evidence-based practices in aesthetic medicine. The company’s focus on innovation, personalized treatment outcomes, and clinician education demonstrates its leadership in the field. As new products like TrenibotulinumtoxinE await regulatory approval, Allergan Aesthetics continues to set the standard for the future of facial aesthetics.

Read the source